NYSE · Healthcare · Drug Manufacturers—General
AbbVie Inc. (ABBV)
As of Sep 25, 4:03 PM ET, AbbVie (ABBV) last traded at $264.34, down 0.29% on the day. Its TickerHum research score is 55/100 (average). It reported revenue of $64.39B for the twelve months ending 2026-06-30, up 10.4% year over year, with a 26.2% operating margin.
Ratings
- Valuation: 42/100 — Strongest input: price / sales (ttm) 7.3x. Weakest: price / earnings (ttm) 74.7x.
- Growth: 76/100 — Strongest input: diluted eps growth (ttm, yoy) +68.6 %. Weakest: revenue growth (ttm, yoy) +10.4 %.
- Profitability: 65/100 — Strongest input: operating margin 26.2 %. Weakest: net margin 9.8 %.
- Financial health: 1/100 — Strongest input: current ratio 0.81. Weakest: cash / long-term debt 0.11.
- Momentum: 70/100 — Strongest input: price vs 200-day average +14.7 %. Weakest: 3-month return +4.3 %.
- Attention: 50/100 — Strongest input: headlines in the last 7 days 36. Weakest: volume vs 3-month average 0.4x.
- Risk: 78/100 — Strongest input: annualised volatility (1y) 26.4 %. Weakest: max drawdown (1y) -19.2 %.
- Data confidence: 87/100 — Strongest input: latest financial period age (days) 63 d. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $64.39B | TTM ending 2026-06-30 · 10-Q |
| Revenue growth | 10.4% | TTM ending 2026-06-30 · 10-Q |
| Net income | $6.31B | TTM ending 2026-06-30 · 10-Q |
| Diluted EPS | $3.54 | TTM ending 2026-06-30 · 10-Q |
| Operating margin | 26.2% | TTM ending 2026-06-30 · 10-Q |
| Net margin | 9.8% | TTM ending 2026-06-30 · 10-Q |
| Free cash flow | $18.21B | TTM ending 2026-06-30 · 10-Q |
| Cash | $6.57B | as of 2026-06-30 · 10-Q |
| Long-term debt | $62.48B | as of 2026-06-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0001551152).
Compare AbbVie with its closest competitors
- AbbVie vs Bristol-Myers Squibb (ABBV vs BMY) — Same industry (Drug Manufacturers—General); market cap 0.27x; shares: immunology, oncology
- AbbVie vs Merck & Co. (ABBV vs MRK) — Same industry (Drug Manufacturers—General); market cap 0.79x; shares: oncology
- AbbVie vs Amgen (ABBV vs AMGN) — Same industry (Drug Manufacturers—General); market cap 0.48x; shares: oncology
- AbbVie vs Eli Lilly and (ABBV vs LLY) — Same industry (Drug Manufacturers—General); market cap 2.4x; shares: oncology
- AbbVie vs Gilead Sciences (ABBV vs GILD) — Same industry (Drug Manufacturers—General); market cap 0.40x; shares: oncology
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.